We read with great interest the ANITA study by Genovesi et al., which provides a crucial real-world snapshot of molecular profiling and matched targeted therapy in advanced cholangiocarcinoma (CCA) across Italy [1]. The authors are to be commended for clearly demonstrating the dramatic survival benefit when patients with ESCAT I-III alterations receive matched targeted therapy (median overall survival 68.0 months), and for starkly highlighting the persistent chasm between the increasing availability of extended molecular profiling (EMP) and the dismal rate of subsequent treatment access (18.7%).
We read with great interest the ANITA study by Genovesi et al., which provides a crucial real-world snapshot of molecular profiling and matched targeted therapy in advanced cholangiocarcinoma (CCA) across Italy [1]. The authors are to be commended for clearly demonstrating the dramatic survival benefit when patients with ESCAT I-III alterations receive matched targeted therapy (median overall survival 68.0 months), and for starkly highlighting the persistent chasm between the increasing availability of extended molecular profiling (EMP) and the dismal rate of subsequent treatment access (18.7%).